We have been receiving reports of people diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), and ischemic stroke as possible semaglutide blood clots side effects. Ozempic, Rybelsus, and Wegovy are drugs with semaglutide as their active ingredient. Semaglutide Blood Clots Side Effects: DVT and Pulmonary … [Read more...]
Ozempic Side Effects Include Eye Problems With Possible Vision Loss
In July 2024 we learned from a recent medical study that Ozempic side effects include eye problems with possible vision loss. More specifically, nonarteritic anterior ischemic optic neuropathy (NAION) has been linked to semaglutide — the active ingredient in Ozempic as well as Wegovy and Rybelsus. As such, this finding about the new NAION Ozempic … [Read more...]
Blood Clots When Using Wegovy, Rybelsus, or Ozempic
Drug injury lawsuits that might be filed against the pharmaceutical company Novo Nordisk involving blood clots when using Wegovy, Rybelsus, or Ozempic are somewhat like the federal court Wegovy/Rybelsus/Ozempic MDL lawsuits involving gastrointestinal and stomach problems because they would involve similar — but different — liability issues, such … [Read more...]
Wegovy / Rybelsus / Ozempic DVT Blood Clots Side Effects Cases
Wegovy, Rybelsus, and Ozempic DVT blood clots side effects have not received as much attention as adverse event reports that involve severe stomach conditions such as gastroparesis, gastric stasis, and stomach paralysis. Ozempic, Wegovy, and Rybelsus are three popular GLP-1 receptor agonists containing semaglutide that are increasingly used as … [Read more...]
Gastroparesis Cases Involving Ozempic, Rybelsus, Wegovy, and Trulicity as Weight-loss Drugs
We are handling gastroparesis cases involving Ozempic, Rybelsus, Wegovy, and Trulicity as drug injury lawsuits filed against the responsible pharmaceutical companies. In this piece, we point out two medical journal articles that present a few gastroparesis cases involving the use of semaglutide (Ozempic, Rybelsus, Wegovy) or dulaglutide … [Read more...]
Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
Patients who use drugs containing semaglutide are at an increased risk of gastroparesis, according to an October 2023 medical journal article about patients who used two different types of weight-loss drugs. The Novo Nordisk drugs Wegovy, Rybelsus, and Ozempic each have semaglutide as their active ingredient. Accordingly, Wegovy, Rybelsus, and … [Read more...]
Ozempic Gastrointestinal-related Adverse Events Cases Increasing
The number of Ozempic gastrointestinal-related adverse events cases, including ileus cases, that have been reported to the FDA during the first 6 months of 2023 was covered in this September 28, 2023 article, “FDA Adds New Warning for Ileus to Semaglutide (Ozempic) Label”, published September 28, 2023, on the HCPLive® website: According to the US … [Read more...]
Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
In recent years we have seen an increasing number of adverse event reports for three Novo Nordisk semaglutide-containing drugs — Ozempic, Rybelsus, and Wegovy — that involve severe stomach conditions, including: Gastroparesis Gastric Stasis Stomach Paralysis The most common symptoms are nausea and vomiting, which can be severely … [Read more...]
Ozempic Gastric Side Effects: Gastroparesis, Stomach Paralysis, Intestinal Blockages
In the several years since Ozempic was approved by the FDA, there have been adverse event reports of Ozempic gastric side effects such as gastroparesis, stomach paralysis, and intestinal blockage cases in patients using Ozempic. Gastroparesis may also be called delayed gastric emptying. Gastroparesis is a long-term, chronic condition that can be … [Read more...]
Ozempic Safety Issues Update: July 2023 Edition
In this Ozempic safety issues update we report on thyroid cancer, gallbladder disease, and suicidal thoughts as being possible Ozempic side effects. The European Medicines Agency (EMA) recently announced it has begun an investigation into Ozempic and suicidal thoughts as well as self-harm. From July 11, 2023 document “EMA statement on ongoing … [Read more...]